Ipsen S.A. (Euronext: IPN; ADR: IPSEY)

https://www.ipsen.com

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). *

	Start	2007-08-25 existent
	Industry	pharmaceutical

	Street	42 rue du Docteur Blanche
	City	75016 Paris
	Tel	+33-1-443043-43
		Address record changed: 2020-12-02

Basic data	Employees	F: 1,001 to 5,000 (2022-06-27)
	Currency	EUR
	Annual sales	1,671,100,000 (revenue, consolidated (2016) 2016-12-31)
	Profit	226,600,000 (2016-12-31)
	Cash	425,500,000 (2016-12-31)

		* Document for »About Section«: Ipsen S.A.. (6/27/22). "Press Release: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology". Paris & Cambridge, MA.

		Record changed: 2023-01-20

Picture EasyFairs Connect in Pharma 2023 Geneva Networking 650x200px

More documents for Ipsen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)